Systolic blood pressure variability: risk of cardiovascular events, chronic kidney disease, dementia, and death

Xunjie Cheng, Chao Song, Feiyun Ouyang, Tianqi Ma, Lingfang He, Fang Fang, Guogang Zhang, Jiaqi Huang, Yongping BaiEuropean 2025 · DOI

TL;DR

This study reveals that not just high blood pressure, but how much your blood pressure fluctuates over time (systolic blood pressure variability, or SBPV) significantly increases your risk of cardiovascular disease, chronic kidney disease, and even death. The key takeaway is that managing these fluctuations, not just the average blood pressure, is crucial for long-term health.

What Problem Does This Paper Address?

We all know high blood pressure is bad. But what about the day-to-day ups and downs of blood pressure? This paper tackles the question of whether variability in systolic blood pressure (SBPV) over time, independent of the average blood pressure, is a significant risk factor for serious health outcomes. Previous research has hinted at this link, but this study goes further by examining how changes in SBPV over two distinct periods, and the patterns of these changes, relate to a broad range of adverse events, including cardiovascular disease (CVD), chronic kidney disease (CKD), dementia, and overall mortality. The challenge is that SBPV is often measured over a single period, neglecting its dynamic nature, and this study aims to fill that gap.

Methods

The researchers utilized a large dataset from the UK Biobank, comprising over 36,000 participants with primary care data. They defined two periods for SBP measurement: Period 1 (5-10 years before enrollment) and Period 2 (0-5 years before enrollment). SBPV was calculated as the standard deviation of at least three SBP readings within each period.

The core of their analysis involved:

  • Absolute Changes in SBPV: They quantified the change in SBPV by subtracting Period 1 SBPV from Period 2 SBPV and categorized participants into tertiles based on this change (greatest reduction to greatest increase).
  • SBPV Change Patterns: Participants were also classified based on their SBPV levels in both periods (e.g., consistently low, low-to-high, consistently high).
  • Statistical Modeling: Cox proportional hazards models were employed to assess the association between these SBPV changes and patterns with the risk of various clinical outcomes, adjusting for a comprehensive set of covariates including age, sex, lifestyle factors, and baseline medical history.

Datasets

The primary dataset used in this study was the UK Biobank. This is a large-scale, prospective cohort study that collected detailed health and lifestyle information from half a million participants. For this specific study, data from approximately 36,000 participants with available primary care data were utilized. No new benchmark datasets were introduced.

Key Insights and Ideas

  • Temporal Dynamics Matter: The study strongly suggests that focusing solely on average blood pressure is insufficient. The trend of SBPV over time is a critical, independent predictor of health outcomes.
  • Increasing SBPV is a Red Flag: An increase in SBPV from an earlier period to a more recent one significantly elevates the risk of CVD, CKD, and mortality. This implies that even if blood pressure is within a "normal" range, increasing variability is a warning sign.
  • Consistently High SBPV is Particularly Risky: Individuals who consistently exhibit high SBPV across both measurement periods face a substantially higher risk of a wide array of adverse events compared to those with consistently low SBPV.
  • Broader Impact Beyond Cardiovascular Events: The findings extend beyond traditional cardiovascular outcomes to include chronic kidney disease and overall mortality, highlighting the systemic impact of blood pressure lability.

Key Results

The study found that:

  • Increased SBPV from Period 1 to Period 2 was significantly associated with an increased risk of:
  • Cardiovascular Disease (CVD): 23%-33% increased risk for those with the greatest increase in SBPV compared to the greatest decrease.
  • Coronary Heart Disease (CHD): Similar increased risk.
  • Stroke: Similar increased risk.
  • Chronic Kidney Disease (CKD): 23%-33% increased risk.
  • Overall Mortality: 23%-33% increased risk.
  • Consistently High SBPV (compared to consistently low SBPV) was associated with a 28%-46% increased risk of CVD, CHD, stroke, AF, HF, CKD, and overall mortality.
  • While associations were observed for AF, HF, and dementia with increasing SBPV, they did not reach the stringent statistical significance threshold (P < .005) in all models.

Limitations and Future Work

The authors acknowledge several limitations:

  • Primary Care Data: The use of primary care data means SBP measurements might not have been standardized in terms of frequency or conditions under which they were taken.
  • Covariate Data: Covariate data were self-reported, potentially introducing recall bias.
  • Exclusion of Participants: Participants with missing covariate data were excluded, which could introduce bias.
  • Small Event Counts: The number of cases for AF, HF, and dementia was relatively small, potentially limiting statistical power for these outcomes.
  • Observational Nature: The study is observational, so direct causal relationships cannot be definitively established.
  • Generalizability: The UK Biobank population is predominantly White European, limiting generalizability to other ethnic groups.

Future work suggested includes:

  • Randomized Controlled Trials (RCTs): Ad hoc designed RCTs are needed to establish causality and explore strategies for optimal SBPV management.
  • Further Investigation of Mechanisms: More research is needed to understand the underlying biological mechanisms linking SBPV to adverse outcomes.
  • Identification of Modifiable Factors: Identifying factors that can effectively modify SBPV (e.g., lifestyle, specific medications) is crucial.
  • Longer Follow-up: Continued follow-up of the study population is recommended to re-evaluate associations with less frequent outcomes.

Summary updated

Abstract

An increase in SBPV over time was associated with an elevated risk of CVD, CKD, and overall mortality. These findings provide compelling evidence to inform the importance for the management of SBPV in clinical practice.
BibTeX
@inproceedings{cheng2025systolic,
  author = {Xunjie Cheng and Chao Song and Feiyun Ouyang and Tianqi Ma and Lingfang He and Fang Fang and Guogang Zhang and Jiaqi Huang and Yongping Bai},
  title = {{Systolic blood pressure variability: risk of cardiovascular events, chronic kidney disease, dementia, and death}},
  booktitle = {European},
  year = {2025},
  doi = {10.1093/eurheartj/ehaf256},
}
Figure